Please login to the form below

Not currently logged in
Email:
Password:

nusinersen

This page shows the latest nusinersen news and features for those working in and with pharma, biotech and healthcare.

Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA

Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA

If it does get a green light, risdiplam would compete in the market with Biogen’s blockbuster antisense-based SMA medicine  Spinraza (nusinersen) as well as Novartis’ recently-approved gene therapy 

Latest news

More from news
Approximately 4 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    95.  Ionis (US). Biogen (US). Exercise option .  Nusinersen, in phase III for treatment for spinal muscular atrophy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Article: Market access in Brazil

    In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics